Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Ribamidine 1-[(2R,3R,4S,5R)-3,4- dihydroxy-5...

Synonyms: Taribavirin, SureCN40670, AC1L9PNE, ICN 3142, NSC627433, ...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ribamidine

The pharmacokinetics of [(14)C]viramidine, a prodrug of ribavirin, were studied in rats (30 mg/kg of body weight) and monkeys (10 mg/kg) following intravenous (i.v.) and oral administration [1].
Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection [2].
Viramidine is a liver-targeting prodrug of ribavirin with much less potential for hemolytic anemia [3].

Chemical compound and disease context of Ribamidine

Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C [4].

Associations of Ribamidine with other chemical compounds

Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers [5].
Adverse event rates were similar between groups except for diarrhea (viramidine 29.5%; ribavirin 15.7%; p<0.0001) [6].

References

Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Lin, C.C., Luu, K., Lourenco, D., Yeh, L.T. Antimicrob. Agents Chemother. (2003) [Pubmed]
Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. Aora, S., Xu, C., Teng, A., Peterson, J., Yeh, L.T., Gish, R., Lau, D., Rossi, S., Lin, C.C. Journal of clinical pharmacology. (2005) [Pubmed]
Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats. Fang, C., Srivastava, P., Lin, C.C. Journal of applied toxicology : JAT. (2003) [Pubmed]
Definition and management of anemia in patients infected with hepatitis C virus. McHutchison, J.G., Manns, M.P., Longo, D.L. Liver Int. (2006) [Pubmed]
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. Lin, C.C., Philips, L., Xu, C., Yeh, L.T. Journal of clinical pharmacology. (2004) [Pubmed]
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. Marcellin, P., Gish, R.G., Gitlin, N., Heise, J., Halliman, D.G., Chun, E., Rodriguez-Torres, M. J. Hepatol. (2010) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.